Skeletal-Muscle Relaxants and Neuromuscular Blockade

A rapid connection of drug targets, neuromuscular effects, clinical uses, important adverse effects and emergency management.

Structured according to the supplied AIM Concept Integration requirements. :contentReference[oaicite:0]{index=0}

THE TOPIC IN ONE CONNECTED FLOW

Skeletal-muscle relaxants reduce muscle activity by acting at the neuromuscular junction, within the central nervous system or directly inside skeletal muscle. The site of action determines whether the drug produces surgical paralysis, reduces spasticity or treats excessive calcium-driven muscle contraction.

Normal transmission
Motor nerve releases acetylcholine at the neuromuscular junction

→

Nₘ receptor
Receptor activation produces end-plate depolarization and contraction

→

Drug intervention
Non-depolarizing blockade or persistent depolarization prevents repeated muscle action potentials

→

Functional change
Skeletal muscle becomes weak or flaccidly paralyzed

→

Clinical benefit
Intubation, surgery or mechanical ventilation becomes easier

→

Essential caution
Paralysis requires anesthesia, analgesia, monitoring and ventilatory support

Central pathway
Baclofen, tizanidine, diazepam or cyclobenzaprine → reduced central motor activity → reduced spasticity or painful muscle spasm.

Calcium pathway
Excess sarcoplasmic calcium release → sustained contraction and hypermetabolism → dantrolene reduces calcium release and limits the crisis.

KEY CLINICAL CONNECTIONS

Reversal of Non-Depolarizing Blockade

Neostigmine inhibits acetylcholinesterase
→
acetylcholine rises
→
it competes with the blocker
→
muscle function returns.

Muscarinic effects
→
bradycardia and secretions
→
give glycopyrrolate or atropine.

Succinylcholine Apnea

Reduced or atypical butyrylcholinesterase
→
delayed succinylcholine metabolism
→
prolonged respiratory-muscle paralysis.

Maintain sedation and ventilation
→
wait for metabolism and recovery
→
document the reaction.

Malignant Hyperthermia

Volatile anesthetic or succinylcholine
→
uncontrolled muscle calcium release
→
rigidity, rising carbon dioxide and acidosis.

Dantrolene
→
reduced sarcoplasmic calcium release
→
reduced contraction and heat production.

AIM HIGH-YIELD INTEGRATION REVIEW

⭐ Non-depolarizing blockers:
competitive Nₘ receptor blockade
→
inadequate end-plate depolarization
→
flaccid paralysis with train-of-four fade.

⭐ Succinylcholine Phase I:
receptor activation
→
persistent depolarization
→
sodium-channel inactivation
→
fasciculations followed by paralysis.

Repeated succinylcholine exposure
→
end-plate desensitization
→
Phase II block with a pattern resembling non-depolarizing blockade.

Burns, denervation or major muscle injury
→
increased extrajunctional receptors
→
excessive potassium release after succinylcholine
→
dangerous arrhythmia risk.

Baclofen activates GABA_B receptors
→
reduced spinal excitatory transmission
→
reduced spasticity; abrupt withdrawal may cause rebound excitation.

Tizanidine activates central α₂ receptors
→
reduced motor-neuron activity
→
reduced tone with possible sedation and hypotension.

⭐ Malignant hyperthermia:
uncontrolled skeletal-muscle calcium release
→
rigidity and hypermetabolism
→
dantrolene treats the underlying mechanism.

Visible limb movement
→
does not guarantee complete airway-muscle recovery
→
confirm neuromuscular recovery before extubation.

AIM Exam Trap
Neostigmine can reverse competitive non-depolarizing blockade, but it does not reverse an initial Phase I succinylcholine block and may prolong it.